The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline
Open accessThe DOI matches its Crossref record; 237 of the 241 references it cites were found in a registry or an index.
Abstract
Objective: To develop clinical practice guidelines for the management of patients with primary aldosteronism. Participants: The Task Force included a chair, selected by the Clinical Guidelines Subcommittee of the Endocrine Society, six additional experts, a methodologist, and a medical writer. The guideline was cosponsored by American Heart Association, American Association of Endocrine Surgeons, European Society of Endocrinology, European Society of Hypertension, International Association of Endocrine Surgeons, International Society of Endocrinology, International Society of Hypertension, Japan Endocrine Society, and The Japanese Society of Hypertension. The Task Force received no corporate funding or remuneration. Evidence: We searched for systematic reviews and primary studies to formulate the key treatment and prevention recommendations. We used the Grading of Recommendations, Assessment, Development, and Evaluation group criteria to describe both the quality of evidence and the strength of recommendations. We used “recommend” for strong recommendations and “suggest” for weak recommendations. Consensus Process: We achieved consensus by collecting the best available evidence and conducting one group meeting, several conference calls, and multiple e-mail communications. With the help of a medical writer, the Endocrine Society's Clinical Guidelines Subcommittee, Clinical Affairs Core Committee, and Council successfully reviewed the drafts prepared by the Task Force. We placed the version approved by the Clinical Guidelines Subcommittee and Clinical Affairs Core Committee on the Endocrine Society's website for comments by members. At each stage of review, the Task Force received written comments and incorporated necessary changes. Conclusions: For high-risk groups of hypertensive patients and those with hypokalemia, we recommend case detection of primary aldosteronism by determining the aldosterone-renin ratio under standard conditions and recommend that a commonly used confirmatory test should confirm/exclude the condition. We recommend that all patients with primary aldosteronism undergo adrenal computed tomography as the initial study in subtype testing and to exclude adrenocortical carcinoma. We recommend that an experienced radiologist should establish/exclude unilateral primary aldosteronism using bilateral adrenal venous sampling, and if confirmed, this should optimally be treated by laparoscopic adrenalectomy. We recommend that patients with bilateral adrenal hyperplasia or those unsuitable for surgery should be treated primarily with a mineralocorticoid receptor antagonist.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 Algorithm for the detection, confirmation, subtype testing, and treatment of PA. a We recommend unilateral laparoscopic adrenalectomy for patients with documented unilateral PA (ie, APA or UAH) (1 ⎪ QQQE ). If a patient is unable or unwilling to undergo surgery, we recommend medical treatment including a MR antagonist (1 ⎪ QQQE ). If an ARR-positive patient is unwilling or unable to undergo further investigations, we similarly recommend medical treatment including an MR antagonist (1 ⎪ QQEE ). b Instead of proceeding directly to subtype classification, we recommend that patients with a positive ARR undergo one or more confirmatory tests to definitively confirm or exclude the diagnosis (1 ⎪ QQEE ). However, in the setting of spontaneous hypokalemia, undetectable renin, and PAC > 20 ng/dL (550 pmol/L), we suggest that there may be no need for further confirmatory testing (2 ⎪ QEEE ). c We recommend that when surgical treatment is feasible and desired by the patient, an experienced radiologist should use AVS to make the distinction between unilateral and bilateral adrenal disease (1 ⎪ QQQE ). Younger patients ( < age 35) with spontaneous hypokalemia, marked aldosterone excess, and unilateral adrenal lesions with radiological features consistent with a cortical adenoma on adrenal CT scan may not need AVS before proceeding to unilateral adrenalectomy (2 ⎪ QEEE ). [Adapted from J. W. Funder et al: Case detection, diagnosis, and treatment of patients with primary aldosteronism: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab . 2008;93:3266-3281 (3), with permission. © Endocrine Society.]](https://figures.cochat.ai/paper-figures/aaade82f5c4b425bbdee69e74321806d/the-management-of-primary-aldosteronism-case-detection-diagnosis-and-treatment-figure-1.png)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The most common types of secondary hypertension in adults are renal parenchymal disease, renovascular hypertension, primary aldosteronism, chronic sleep apnea, and substance/drug-induced.”
From 2020 International Society of Hypertension Global Hypertension Practice Guidelines (2020) · cites this paper as [116]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A specific cause of secondary hypertension can be identified in 5%-10% of hypertensive patients (Table 11).”
From 2020 International Society of Hypertension Global Hypertension Practice Guidelines (2020) · cites this paper as [116]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Early diagnosis of secondary hypertension and the institution of appropriate targeted treatment have the potential to cure hypertension in some patients or improve BP control/reduce the number of prescribed antihypertensive medications in others.”
From 2020 International Society of Hypertension Global Hypertension Practice Guidelines (2020) · cites this paper as [116]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Hypokalemia, which reduces aldosterone secretion, should be corrected with oral K+ supplements before testing.”
From Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association (2018) · cites this paper as [289]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Patients with unilateral disease (50%; aldosterone-producing adenoma or, much less frequently, unilateral hyperplasia) respond to unilateral laparoscopic adrenalectomy with complete cure (≈50%) or improvement (≈50%) in BP control.”
From Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association (2018) · cites this paper as [289]
Experimental — accuracy not yet measured
11 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(2013) · European Heart Journal · doi:10.1093/eurheartj/eht151 · Cited by 13,655
Grading quality of evidence and strength of recommendations
(2004) · BMJ · doi:10.1136/bmj.328.7454.1490 · Cited by 8,477 · cited 1×
“The Task Force followed the approach recommended by the Grading of Recommendations, Assessment, Development, and Evaluation group, an international group with expertise in the development and implementation of evidence-based guidelines (2).”
MethodNational High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents (2004) · PEDIATRICS · doi:10.1542/peds.114.2.s2.555 · Cited by 6,938
Mancia, G., Fagard, R., Narkiewicz, K., Redón, J., Zanchetti, A., Böhm, M., Christiaens, T., Cifkova, R., De Backer, G., Dominiczak, A., et al. (2013) · Journal of Hypertension · doi:10.1097/01.hjh.0000431740.32696.cc · Cited by 5,655
Pitt, B., Remme, W., Zannad, F., Neaton, J., Martinez, F., Roniker, B., Bittman, R., Hurley, S., Kleiman, J., & Gatlin, M. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030207 · Cited by 4,941
(1997) · Archives of Internal Medicine · doi:10.1001/archinte.1997.00440420033005 · Cited by 3,777
(2003) · Journal of Hypertension · doi:10.1097/00004872-200311000-00002 · Cited by 2,672
Funder, J. W., Carey, R. M., Fardella, C., Gomez-Sanchez, C. E., Mantero, F., Stowasser, M., Young, W. F., & Montori, V. M. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0104 · Cited by 1,554 · cited 3×
“The recommendations and suggestions made by the Task Force were subject to extensive consultation before being published in the Journal of Clinical Endocrinology and Metabolism in 2008 (3).”
MethodSelf-citationEvidence for an increased rate of cardiovascular events in patients with primary aldosteronism
Milliez, P., Girerd, X., Plouin, P.-F., Blacher, J., Safar, M. E., & Mourad, J.-J. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.01.015 · Cited by 1,547 · cited 2×
“Several outcome studies also have provided evidence that PA patients are particularly at risk of cardiovascular/ renal complications, including arrhythmias, myocardial infarction, strokes, chronic kidney disease, and death, compared with age-, sex-, and BP-matched essential hypertensives (30, 33, 156).”
BackgroundResultA prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients
Rossi, G. P., Bernini, G., Caliumi, C., Desideri, G., Fabris, B., Ferri, C., Ganzaroli, C., Giacchetti, G., Letizia, C., Maccario, M., et al. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.07.059 · Cited by 1,467 · cited 2×
“However, some groups have suggested that when clinicians administer a bolus injection of cosyntropin and sample the adrenal veins simultaneously, cosyntropin does not improve the diagnostic accuracy of AVS, and, in fact, cosyntropin may increase secretion from the nonadenomatous gland to a greater degree than from the…”
BackgroundSelf-citation
Research works printed but not linked: 3
- 15. Tucker RM, Labarthe DR. Frequency of surgical treatment for hypertensioninadultsattheMayoClinicfrom1973through1975. Mayo Clin Proc . 1977;52:549-545.
- 133. FardellaCE,PintoM,MossoL,Gómez-SánchezC,JalilJ,Montero J. Genetic study of patients with dexamethasone-suppressible aldosteronismwithoutthechimericCYP11B1/CYP11B2gene. J Clin Endocrinol Metab . 2001;86:4805-4807.
- 169. Jacobsen NE, Campbell JB, Hobart MG. Laparoscopic versus openadrenalectomyforsurgicaladrenaldisease. CanJUrol . 2003; 10:1995-1999.
Cited by
Items 101–200 of 1,002
Detecting primary aldosteronism in Australian primary care: a prospective study
Libianto, R., Russell, G. M., Stowasser, M., Gwini, S. M., Nuttall, P., Shen, J., Young, M. J., Fuller, P. J., & Yang, J. (2022) · The Medical Journal of Australia · doi:10.5694/mja2.51438 · Cited by 110
Self-citationReel, P. S., Reel, S., van Kralingen, J. C., Langton, K., Lang, K., Erlic, Z., Larsen, C. K., Amar, L., Pamporaki, C., Mulatero, P., et al. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.104276 · Cited by 112
Self-citationClinical Outcomes After Unilateral Adrenalectomy for Primary Aldosteronism
Vorselaars, W. M. C. M., Nell, S., Postma, E. L., Zarnegar, R., Drake, F. T., Duh, Q., Talutis, S. D., McAneny, D. B., McManus, C. M., Lee, J. A., et al. (2019) · JAMA Surgery · doi:10.1001/jamasurg.2018.5842 · Cited by 110
The Biology of Normal Zona Glomerulosa And Aldosterone-Producing Adenoma: Pathological Implications
Seccia, T. M., Caroccia, B., Gómez-Sánchez, E. P., Gómez-Sánchez, C. E., & Rossi, G. P. (2018) · Endocrine Reviews · doi:10.1210/er.2018-00060 · Cited by 120
SIMBA: using Kolb’s learning theory in simulation-based learning to improve participants’ confidence
Davitadze, M., Ooi, E., Ng, C. Y., Zhou, D., Thomas, L., Hanania, T., Blaggan, P., Evans, N., Chen, W., Melson, E., et al. (2022) · BMC Medical Education · doi:10.1186/s12909-022-03176-2 · Cited by 107
Ichijo, T., Ueshiba, H., Nawata, H., & Yanase, T. (2019) · Endocrine Journal · doi:10.1507/endocrj.ej18-0486 · Cited by 103
2019 Chinese guideline for the management of hypertension in the elderly.
Hua, Q., Fan, L. H., & Li, J. (2019) · PubMed Central · doi:10.11909/j.issn.1671-5411.2019.02.001 · Cited by 116
The Pathophysiology and Treatment of Hypertension in Patients With Cushing's Syndrome
Barbot, M., Ceccato, F., & Scaroni, C. M. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00321 · Cited by 104
Discordance between imaging and immunohistochemistry in unilateral primary aldosteronism
Nanba, A. T., Nanba, K., Byrd, J. B., Shields, J. J., Giordano, T. J., Miller, B. S., Rainey, W. E., Auchus, R. J., & Turcu, A. F. (2017) · Clinical Endocrinology · doi:10.1111/cen.13442 · Cited by 100
Inoue, K., Goldwater, D. S., Allison, M., Seeman, T. E., Kestenbaum, B. R., & Watson, K. E. (2020) · Hypertension · doi:10.1161/hypertensionaha.120.15006 · Cited by 105
“In this analysis, we defined high aldosterone when they showed >150 pg/mL.(2,33)”
BackgroundMethodInfluentialHigh-resolution daily profiles of tissue adrenal steroids by portable automated collection
Upton, T. J., Zavala, E., Methlie, P., Kämpe, O., Tsagarakis, S., Øksnes, M., Bensing, S., Vassiliadi, D. A., Grytaas, M. A., Botusan, I. R., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.adg8464 · Cited by 94
Bertherat, J. Y., Bourdeau, I., Bouys, L., Chasseloup, F., Kamenický, P., & Lacroix, A. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnac034 · Cited by 100
Biomarkers to Guide Medical Therapy in Primary Aldosteronism
Hundemer, G. L., Leung, A. A. C., Kline, G. A., Brown, J. M., Turcu, A. F., & Vaidya, A. (2023) · Endocrine Reviews · doi:10.1210/endrev/bnad024 · Cited by 97
Popoviciu, M. S., Păduraru, L., Nutas, R. M., Ujoc, A. M., Yahya, G., Metwally, K. A., & Cavalu, S. D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241612676 · Cited by 108
Brown, C., & Corr, S. A. (2007) · Veterinary and Comparative Orthopaedics and Traumatology · doi:10.1160/vcot-07-02-0013 · Cited by 109
Ohya, Y., Arakawa, K., Arata, N., Arima, S., Arima, H., Asayama, K., Dohi, Y., Fukami, A., Furuhashi, M., Goto, K., et al. (2026) · Hypertension Research · doi:10.1038/s41440-025-02462-y · Cited by 107
Seccia, T. M., Letizia, C., Muiesan, M. L., Lerco, S., Cesari, M., Bisogni, V., Petramala, L., Maiolino, G., Volpin, R., & Rossi, G. P. (2019) · Journal of Hypertension · doi:10.1097/hjh.0000000000002250 · Cited by 96
“between 26 and 100, and a PAC>15 ng/dl) at the first and a repeated test after a further 1 month wash-out, a confirmatory (captopril challenge) test was performed to rule out false positive results [16].”
BackgroundMethodInfluentialHypertension: The role of biochemistry in the diagnosis and management
O’Shea, P. M., Griffin, T. P., & Fitzgibbon, M. C. (2016) · Clinica Chimica Acta · doi:10.1016/j.cca.2016.12.014 · Cited by 103
Diagnosis and management of primary aldosteronism
Vilela, L. A. P., & Almeida, M. Q. (2017) · Archives of Endocrinology and Metabolism · doi:10.1590/2359-3997000000274 · Cited by 101
“In patients with an onset of confirmed PA earlier than 20 years of age, and in those who have a family history of PA or stroke at a young age (< 40 years), the Endocrine Society Clinical Practice Guideline of PA suggests genetic testing for familial PA type I (glucocorticoid remediable aldosteronism) and type III (cau…”
BackgroundMethodInfluentialLeung, A. A., Symonds, C. J., Hundemer, G. L., Ronksley, P. E., Lorenzetti, D. L., Pasieka, J. L., Harvey, A., & Kline, G. A. (2022) · Hypertension · doi:10.1161/hypertensionaha.122.19377 · Cited by 89
“EH; PA based on a combination of (1) ARR >30 ng/dL per ng/mL/h (using PRA) and (2) abnormal SIT test (postinfusion PAC >10 ng/dL) or 24”
BackgroundMethodInfluentialMaiolino, G., Rossitto, G., Bisogni, V., Cesari, M., Seccia, T. M., Plebani, M., Rossi, G. P., Semplicini, A., Ganzaroli, C., Pessina, A. C., et al. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.117.005574 · Cited by 93
“highly specialized referral centers.(1,3,5) Hence, to the end of selecting the patients for AVS, both the Endocrine Society and the Japanese guidelines concur in supporting the use of confirmatory tests.”
BackgroundMethodSelf-citationOutcomes of a Specialized Clinic on Rates of Investigation and Treatment of Primary Aldosteronism
Liu, Y.-Y., King, J. A., Kline, G. A., Padwal, R. S., Pasieka, J. L., Chen, G., So, B., Harvey, A. M., Chin, A., & Leung, A. A. C. (2021) · JAMA Surgery · doi:10.1001/jamasurg.2021.0254 · Cited by 92
The Saline Infusion Test for Primary Aldosteronism: Implications of Immunoassay Inaccuracy
Eisenhofer, G., Kurlbaum, M., Peitzsch, M., Constantinescu, G. A., Remde, H., Schulze, M., Kaden, D., Müller, L., Fuß, C. T., Kunz, S. L., et al. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab924 · Cited by 89
“The cut-offs for positive (pathologic) versus negative (non-pathologic) results for plasma aldosterone concentrations after the SIT for immunoassays were set at 170 pmol/L (61 ng/L), as defined by Endocrine Society guidelines (1), while the cut-off for LC-MS/MS measurements was defined at 162 pmol/L (58 ng/L), as esta…”
BackgroundMethodResultSelf-citationRege, J., Bandulik, S., Nanba, K., Kosmann, C., Blinder, A., Plain, A., Vats, P., Kumar‐Sinha, C., Lerário, A. M., Else, T., et al. (2023) · Nature Genetics · doi:10.1038/s41588-023-01498-5 · Cited by 91
Self-citationPrimary aldosteronism: a common cause of resistant hypertension
Kline, G. A., Prebtani, A. P. H., Leung, A. A. C., & Schiffrin, E. L. (2017) · Canadian Medical Association Journal · doi:10.1503/cmaj.161486 · Cited by 91
Scholl, U. I., Abriola, L., Zhang, C., Reimer, E. N., Plummer, M. S., Kazmierczak, B. I., Zhang, J., Hoyer, D., Merkel, J. S., Wang, W., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci91733 · Cited by 86
Umakoshi, H., Tsuiki, M., Takeda, Y., Kurihara, I., Itoh, H., Katabami, T., Ichijo, T., Wada, N., Yoshimoto, T., Ogawa, Y., et al. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-01774 · Cited by 88
Self-citationLengton, R., Schoenmakers, M., Penninx, B. W. J. H., Boon, M. R., & van Rossum, E. F. C. (2024) · Clinical Obesity · doi:10.1111/cob.12725 · Cited by 107
“61 In a cohort of Europids, it has been shown that alterations in diurnal cortisol patterns were predictive of future glucose disturbances.”
Longitudinal patterns of recurrence in patients with adrenocortical carcinoma
Glenn, J. A., Else, T., Hughes, D. T., Cohen, M. S., Jolly, S., Giordano, T. J., Worden, F. P., Gauger, P. G., Hammer, G. D., & Miller, B. S. (2018) · Surgery · doi:10.1016/j.surg.2018.04.068 · Cited by 88
Wu, X., Azizan, E. A. B. A., Goodchild, E., Garg, S., Hagiyama, M., Cabrera, C., Fernandes-Rosa, F. L., Boulkroun, S., Kuan, J. L., Tiang, Z., et al. (2023) · Nature Genetics · doi:10.1038/s41588-023-01403-0 · Cited by 87
Self-citationImmunohistochemical Biomarkers of Adrenal Cortical Neoplasms
Mete, Ö., Asa, S. L., Giordano, T. J., Papotti, M. G., Sasano, H., & Volante, M. (2018) · Endocrine Pathology · doi:10.1007/s12022-018-9525-8 · Cited by 90
Cortisol Excess in Patients With Primary Aldosteronism Impacts Left Ventricular Hypertrophy
Adolf, C., Köhler, A., Franke, A., Lang, K., Riester, A., Löw, A., Heinrich, D. A., Bidlingmaier, M., Treitl, M., Ladurner, R., et al. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-00617 · Cited by 81
Self-citationThuzar, M., Young, K., Ahmed, A. H., Ward, G., Wolley, M. J., Guo, Z., Gordon, R. D., McWhinney, B. C., Ungerer, J. P. J., & Stowasser, M. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz150 · Cited by 87
Self-citationResistant Hypertension in People With CKD: A Review
Fay, K., & Cohen, D. L. (2020) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2020.04.017 · Cited by 86
“The prevalence of PA in patients with RH is 11% to 23% and screening with plasma aldosterone concentration and plasma renin activity is mandatory when evaluating RH.(63,64) Although classically associated with hypokalemia and metabolic alkalosis, these findings are present in only a minority of patients with PA.”
BackgroundScreening for primary aldosteronism on and off interfering medications
Li, X., Liang, J., Hu, J., Ma, L., Yang, J., Zhang, A., Jing, Y., Song, Y., Yang, Y., Feng, Z., et al. (2023) · Endocrine · doi:10.1007/s12020-023-03520-6 · Cited by 82
Yang, J., Burrello, J., Goi, J., Reincke, M., Adolf, C., Asbach, E., Brüdgam, D., Li, Q., Song, Y., Hu, J., et al. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00308-5 · Cited by 87
Self-citationDietary Sodium Restriction Increases the Risk of Misinterpreting Mild Cases of Primary Aldosteronism
Baudrand, R., Guarda, F. J., Torrey, J., Williams, G., & Vaidya, A. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-1963 · Cited by 78
“We used this ARR cutoff because it is highly sensitive and therefore ensured that we would not miss potential cases of PA among our population of mild hypertensives on a high dietary sodium balance (6).”
BackgroundMethodInfluentialComprehensive Analysis of Steroid Biomarkers for Guiding Primary Aldosteronism Subtyping
Turcu, A. F., Wannachalee, T., Tsodikov, A., Nanba, A. T., Ren, J., Shields, J. J., O’Day, P. J., Giacherio, D., Rainey, W. E., & Auchus, R. J. (2020) · Hypertension · doi:10.1161/hypertensionaha.119.13866 · Cited by 78
“183 Primary aldosteronism (PA) is traditionally subtyped into unilateral forms, most commonly aldosterone-producing adenoma (APA), or bilateral hyperaldosteronism (BHA).(1) Accurate PA subtyping is essential for guiding clinical management.”
BackgroundMethodInfluentialPerformance of the Aldosterone to Renin Ratio as a Screening Test for Primary Aldosteronism
Hung, A., Ahmed, S., Gupta, A., Davis, A., Kline, G. A., Leung, A. A. C., Ruzicka, M., Hiremath, S. S., & Hundemer, G. L. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab348 · Cited by 82
“Studies where the ARR was measured as a screening test for PA and for which guidelinerecommended dynamic confirmatory testing was performed to confirm the diagnosis of PA were selected (8).”
BackgroundMethodInfluentialThe Value of Targeting CXCR4 With 68Ga-Pentixafor PET/CT for Subtyping Primary Aldosteronism
Zheng, Y., Long, T., Peng, N., Zhen, M., Ye, Q., Zhang, Z., He, Y., Zhi, C., Gan, Y., Luo, M., et al. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad421 · Cited by 76
Primary aldosteronism: molecular medicine meets public health
Azizan, E. A. B. A., Drake, W. M., & Mj, B. (2023) · Nature Reviews Nephrology · doi:10.1038/s41581-023-00753-6 · Cited by 80
“…identification of KCNJ5 -mutant APAs, and may enable the identification of candidates for whom invasive adrenal vein sampling (AVS) can be avoided and substituted with findings of solitary adenoma on CT or MRI, or in whom complete remission of hypertension post-adrenalectomy is most likely 29,202 .”
BackgroundResultInfluentialVilela, L. A. P., Rassi-Cruz, M., Guimaraes, A. G., Moises, C., Freitas, T. C., Alencar, N., Petenuci, J., Goldbaum, T. S., Maciel, A. A. W., Pereira, M. A. A., et al. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-00531 · Cited by 81
Tezuka, Y., Yamazaki, Y., Kitada, M., Morimoto, R., Kudo, M., Seiji, K., Takase, K., Kawasaki, Y., Mitsuzuka, K., Ito, A., et al. (2019) · Hypertension · doi:10.1161/hypertensionaha.118.12064 · Cited by 77
Chen, S.-Y., Chen, J., Huang, W., Puar, T. H. K., Kek, P. C., Chueh, S., Lin, Y., Wu, V., & TAIPAI Study Group (2022) · European Journal of Endocrinology · doi:10.1530/eje-22-0375 · Cited by 78
Clinical Management of Primary Aldosteronism: An Update
Rossi, G. P., Rossi, F. B., Guarnieri, C., Rossitto, G., & Seccia, T. M. (2024) · Hypertension · doi:10.1161/hypertensionaha.124.22642 · Cited by 85
“Instead, to boost cost-effectiveness, popular guidelines recommend screening of only cohorts of patients with an enriched prevalence of PA, 29 a strategy that can lead to miss many cases.”
Umakoshi, H., Ogasawara, T., Takeda, Y., Kurihara, I., Itoh, H., Katabami, T., Ichijo, T., Wada, N., Shibayama, Y., Yoshimoto, T., et al. (2018) · Clinical Endocrinology · doi:10.1111/cen.13582 · Cited by 78
Self-citationIs Primary Aldosteronism Still Largely Unrecognized?
Buffolo, F., Monticone, S., Burrello, J., Tetti, M., Veglio, F., Williams, T. A., & Mulatero, P. (2017) · Hormone and Metabolic Research · doi:10.1055/s-0043-119755 · Cited by 77
“The majority of these studies were published before the release of the first edition of the Endocrine Society Guideline for the treatment and diagnosis of PA in 2008 [4], which can partially explain the wide variation reported for the prevalence of PA, due to the different criteria used for patient selection and di -…”
BackgroundInfluentialMeasurement of Equilibrium Angiotensin II in the Diagnosis of Primary Aldosteronism
Guo, Z., Poglitsch, M., McWhinney, B. C., Ungerer, J. P. J., Ahmed, A. H., Gordon, R. D., Wolley, M. J., & Stowasser, M. (2020) · Clinical Chemistry · doi:10.1093/clinchem/hvaa001 · Cited by 78
Self-citationKeeping primary aldosteronism in mind: Deficiencies in screening at-risk hypertensives
Ruhle, B. C., White, M. G., Alsafran, S. K., Kaplan, E. L., Angelos, P., & Grogan, R. H. (2018) · Surgery · doi:10.1016/j.surg.2018.05.085 · Cited by 74
Burrello, J., Burrello, A., Pieroni, J., Sconfienza, E., Forestiero, V., Rabbia, P., Adolf, C., Reincke, M., Veglio, F., Williams, T. A., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa379 · Cited by 81
Self-citationPeng, K., Liao, H., Chan, C., Lin, W., Yang, S., Tsai, Y., Huang, K., Lin, Y., Chueh, S., & Wu, V. (2020) · Hypertension · doi:10.1161/hypertensionaha.120.15328 · Cited by 76
“Consistent with our findings, previous studies have reported that an APA usually appears as a small nodule, 2 cm in diameter on computed tomography, whereas a larger, benign-appearing unilateral mass could indicate an A/CPA.8,22 We showed that the prevalence of KCNJ5 mutations was 30.8% among patients with a clinical…”
ResultInfluentialPrimary Aldosteronism: Where Are We Now? Where to From Here?
Funder, J. W., & Carey, R. M. (2022) · Hypertension · doi:10.1161/hypertensionaha.121.18761 · Cited by 77
Self-citationPrimary Aldosteronism and Obstructive Sleep Apnea: A Cross-Sectional Multi-Ethnic Study
Buffolo, F., Li, Q., Monticone, S., Heinrich, D. A., Mattei, A., Pieroni, J., Mei, M., Yang, S., Hu, Y., Yang, M., et al. (2019) · Hypertension · doi:10.1161/hypertensionaha.119.13833 · Cited by 77
“However, because there is not a typical phenotype to guide the clinicians, the ES guideline identifies high-risk groups of hypertensive patients that should be screened for PA, including those with OSA.(14,25) While convincing evidence, including a cost-effectiveness study, supports the recommendation of screening pat…”
BackgroundMethodSelf-citationAdrenocortical tumorigenesis: Lessons from genetics
Kamilaris, C. D. C., Hannah‐Shmouni, F., & Stratakis, C. A. (2020) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2020.101428 · Cited by 77
Meyer, L. S., Handgriff, L., Lim, J. S., Udager, A. M., Kinker, I.-S., Ladurner, R., Wildgruber, M., Knösel, T., Bidlingmaier, M., Rainey, W. E., et al. (2021) · Hypertension · doi:10.1161/hypertensionaha.121.17348 · Cited by 75
Self-citationPrimary aldosteronism decreases insulin secretion and increases insulin clearance in humans
Adler, G. K., Murray, G. R., Turcu, A. F., Nian, H., Yu, C., Solorzano, C. C., Manning, R., Peng, D., & Luther, J. M. (2020) · Hypertension · doi:10.1161/hypertensionaha.119.13922 · Cited by 71
“1251 Primary aldosteronism is the most common identifiable cause of resistant hypertension and is associated with increased risk of cardiovascular complications compared with essential hypertension.(1) Primary aldosteronism is also associated with glucose intolerance and an increased risk of type 2 diabetes mellitus,…”
BackgroundLadurner, R., Sommerey, S., Buechner, S., Dietz, A., Degenhart, C., Hallfeldt, K. K. J., & Gallwas, J. K. S. (2017) · European Journal of Clinical Investigation · doi:10.1111/eci.12746 · Cited by 71
“After one year of follow-up, no significant differences were seen between both groups regarding the intensity of antihypertensive medication for obtaining the target blood pressure [12].”
BackgroundResultMeyer, L. S., Wang, X., Sušnik, E., Burrello, J., Burrello, A., Castellano, I., Eisenhofer, G., Fallo, F., Kline, G. A., Knösel, T., et al. (2018) · Hypertension · doi:10.1161/hypertensionaha.118.11465 · Cited by 72
Self-citationDevelopment and validation of subtype prediction scores for the workup of primary aldosteronism
Kobayashi, H. H., Abe, M., Soma, M., Takeda, Y., Kurihara, I., Itoh, H., Umakoshi, H., Tsuiki, M., Katabami, T., Ichijo, T., et al. (2018) · Journal of Hypertension · doi:10.1097/hjh.0000000000001855 · Cited by 74
Self-citationLiddle’s syndrome mechanisms, diagnosis and management
Enslow, B. T., Stockand, J. D., & Berman, J. M. (2019) · Integrated Blood Pressure Control · doi:10.2147/ibpc.s188869 · Cited by 80
“In contrast, plasma renin activity and plasma aldosterone concentration are typically suppressed in other forms of heritable hypertension including Liddle’s syndrome, Congenital adrenal hyperplasia, and apparent mineralocorticoid excess.(21,22,27,28) Genetic testing of the genes coding the three subunits of ENaC, SCNN…”
BackgroundThe Spectrum of Dysregulated Aldosterone Production: An International Human Physiology Study
Parksook, W. W., Brown, J. M., Omata, K., Tezuka, Y., Ono, Y., Satoh, F., Tsai, L. C., Niebuhr, Y., Milks, J., Moore, A., et al. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae145 · Cited by 72
Primary aldosteronism and pregnancy
Morton, A. (2015) · Pregnancy Hypertension · doi:10.1016/j.preghy.2015.08.003 · Cited by 71
Aging and Adrenal Aldosterone Production
Nanba, K., Vaidya, A., & Rainey, W. E. (2017) · Hypertension · doi:10.1161/hypertensionaha.117.10391 · Cited by 78
“patients with PA, early detection of the disease and targeted treatment is recommended.(14)”
BackgroundGuo, Z., Poglitsch, M., McWhinney, B. C., Ungerer, J. P. J., Ahmed, A. H., Gordon, R. D., Wolley, M. J., & Stowasser, M. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-01041 · Cited by 72
Self-citationWannachalee, T., Zhao, L., Nanba, K., Nanba, A. T., Shields, J. J., Rainey, W. E., Auchus, R. J., & Turcu, A. F. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-01182 · Cited by 71
“A major concern has been that cosyntropin might boost aldosterone production from normal zona-glomerulosa cells, concealing an APA (19, 20), but such findings have not been consistent.”
BackgroundMethodInfluentialAdrenal vein sampling: technique and protocol, a systematic review
Quencer, K. B. (2021) · CVIR Endovascular · doi:10.1186/s42155-021-00220-y · Cited by 75
“Main text The recommended technique for lateralization of aldosterone production is adrenal vein sampling (AVS) (Funder et al. 2016; Rossi et al. 2014).”
BackgroundInfluentialDiagnosis and management of resistant hypertension
Schiffrin, E. L., & Fisher, N. D. L. (2024) · BMJ · doi:10.1136/bmj-2023-079108 · Cited by 83
“43 Therefore, recommendations have expanded beyond the original criteria, which included true resistant hypertension, spontaneous or diuretic induced hypokalemia, and adrenal adenoma.”
BackgroundOmura, K., Ota, H., Takahashi, Y., Matsuura, T., Seiji, K., Arai, Y., Morimoto, R., Satoh, F., & Takase, K. (2017) · Hypertension · doi:10.1161/hypertensionaha.116.08375 · Cited by 76
Katabami, T., Fukuda, H., Tsukiyama, H., Tanaka, Y., Takeda, Y., Kurihara, I., Ito, H., Tsuiki, M., Ichijo, T., Wada, N., et al. (2019) · Journal of Hypertension · doi:10.1097/hjh.0000000000002070 · Cited by 71
“com therefore, AdX is generally recommended if the patient agrees to surgery [8,9].”
BackgroundSelf-citationGao, Y., Ding, J., Cui, Y., Li, T., Sun, H., Zhao, D., Zhang, Y., Huo, L., & Tong, A. (2022) · European Radiology · doi:10.1007/s00330-022-09058-x · Cited by 73
“PA diagnosis was based on the clinical guidelines from the subcommittee of the Endocrine Society [9].”
MethodAdrenal GIPR expression and chromosome 19q13 microduplications in GIP-dependent Cushing’s syndrome
Lecoq, A.-L., Stratakis, C. A., Viengchareun, S., Chaligné, R., Tosca, L., Deméocq, V., Hage, M., Berthon, A., Faucz, F. R., Hanna, P., et al. (2017) · JCI Insight · doi:10.1172/jci.insight.92184 · Cited by 66
“criteria of hyperaldosteronism (39) and a significant postprandial and post–GIP infusion renin-independent increase in plasma aldosterone concentration.”
BackgroundHeinrich, D. A., Adolf, C., Holler, F., Lechner, B., Schneider, H., Riester, A., Nirschl, N., Sturm, L., Wang, X., Ladurner, R., et al. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-00996 · Cited by 72
Self-citationThe Burden of Hormonal Disorders: A Worldwide Overview With a Particular Look in Italy
Crafa, A., Calogero, A. E., Cannarella, R., Mongioì, L. M., Condorelli, R. A., Greco, E. A., Aversa, A., & Vignera, S. L. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.694325 · Cited by 79
“Hyperaldosteronism Hypertension, electrolyte imbalances with hypernatremia and hypokalemia that can lead to fatal arrhythmias (8) Pheochromocytoma Hypertension, orthostatic hypotension, fatal arrhythmias, impaired glucose metabolism (9)”
BackgroundKobayashi, H. H., Abe, M., Nakamura, Y., Takahashi, K., Fujita, M., Takeda, Y., Yoneda, T., Kurihara, I., Itoh, H., Tsuiki, M., et al. (2019) · Hypertension · doi:10.1161/hypertensionaha.119.13131 · Cited by 69
Lorenz, K., Langer, P., Niederle, B., Alesina, P. F., Holzer, K., Nies, C., Musholt, T., Goretzki, P. E., Rayes, N., Quinkler, M. O., et al. (2019) · Langenbeck s Archives of Surgery · doi:10.1007/s00423-019-01768-z · Cited by 68
The Role of Aldosterone in OSA and OSA-Related Hypertension
Wang, Y., Li, C. X., Lin, Y. N., Zhang, L. Y., Li, S. Q., Zhang, L., Yan, Y. R., Lu, F., Li, N., & Li, Q. Y. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.801689 · Cited by 72
“Although the current recommendation of the Endocrine Society guideline is that all OSA patients should be screened for PA, irrespective of the grade of HTN (61), the screening rate (2.”
BackgroundBrown, J. M., Wijkman, M. O., Claggett, B. L., Shah, A. M., Ballantyne, C. M., Coresh, J., Grams, M. E., Wang, Z., Yu, B., Boerwinkle, E., et al. (2022) · Hypertension · doi:10.1161/hypertensionaha.122.19134 · Cited by 68
Clinical practice guideline for the management of hypertension in China
Chinese Society of Cardiology, C. M. A., Hypertension Committee of Cross-Straits Medicine Exchange Association, & Cardiovascular Disease Prevention and Rehabilitation Committee, C. A. O. R. M. (2024) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003431 · Cited by 68
Wolley, M. J., Ahmed, A. H., Gordon, R. D., & Stowasser, M. (2016) · Clinical Endocrinology · doi:10.1111/cen.13110 · Cited by 69
Self-citationHundemer, G. L., Baudrand, R., Brown, J. M., Curhan, G. C., Williams, G. H., & Vaidya, A. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-3867 · Cited by 69
Jakobsson, H., Farmaki, K., Sakinis, A., Ehn, O., Johannsson, G., & Ragnarsson, Ó. (2018) · Diagnostic and Interventional Radiology · doi:10.5152/dir.2018.17397 · Cited by 82
Diagnostic approach to low‐renin hypertension
Monticone, S., Losano, I., Tetti, M., Buffolo, F., Veglio, F., & Mulatero, P. (2018) · Clinical Endocrinology · doi:10.1111/cen.13741 · Cited by 74
Aldosterone-Producing Cell Clusters in Normal and Pathological States
Omata, K., Tomlins, S. A., & Rainey, W. E. (2017) · Hormone and Metabolic Research · doi:10.1055/s-0043-122394 · Cited by 67
“When aldosterone is overproduced in one adrenal gland [mostly by CT-scan detectable APA or CT-undetectable unilateral multiple adrenocortical nodules (UMN)] [3], unilateral adrenalectomy is recommended as a likely cure for hyperaldosteronism [1].”
Renin-Angiotensin-Aldosterone System Triple-A Analysis for the Screening of Primary Aldosteronism
Burrello, J., Buffolo, F., Domenig, O., Tetti, M., Pecori, A., Monticone, S., Poglitsch, M., & Mulatero, P. (2019) · Hypertension · doi:10.1161/hypertensionaha.119.13772 · Cited by 69
“The ARR-S using the angiotensin-based PRA marker PRA-S as denominator, and the AA2R, which uses eqAng II directly as the denominator of the diagnostic ratio for PA.”
BackgroundMethodInfluentialSecondary hypertension in adults
Puar, T. H. K., Mok, Y., Debajyoti, R., Khoo, J. J. C., How, C., & Ng, A. (2016) · Singapore Medical Journal · doi:10.11622/smedj.2016087 · Cited by 83
The Low-Renin Hypertension Phenotype: Genetics and the Role of the Mineralocorticoid Receptor
Baudrand, R., & Vaidya, A. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19020546 · Cited by 68
“In most cases of PA, the source of autonomous aldosterone is bilateral or surgery is not pursued due to other complicating factors, and therefore, medical therapy with MR antagonists (such as spironolactone and eplerenone) is recommended [16].”
BackgroundMethodInfluentialPrimary Aldosteronism Diagnosis and Management
Hundemer, G. L., & Vaidya, A. (2019) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2019.08.002 · Cited by 76
Primary Adrenal Insufficiency: Managing Mineralocorticoid Replacement Therapy
Esposito, D., Pasquali, D., & Johannsson, G. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-01928 · Cited by 59
“tion when these antihypertensive drugs are being used (54, 56).”
BackgroundPrevalence of primary aldosteronism in primary care: a cross-sectional study
Käyser, S. C., Deinum, J., Grauw, W. J. D., Schalk, B. W. M., Bor, H. H. J., Lenders, J. W. M., Schermer, T. R., & Biermans, M. C. J. (2018) · British Journal of General Practice · doi:10.3399/bjgp18x694589 · Cited by 67
“20 In brief, hypertension was diagnosed when: (1) office blood pressure was ≥140/90 mmHg on two or more different encounters within 6 months; (2) home blood pressure measurement (electronic device) was ≥135/85 mmHg; (3) 24-hour ambulatory blood pressure monitoring (ABPM) was ≥130/80 mmHg; or (4) daytime ABPM was ≥135/…”
BackgroundNanba, A. T., Wannachalee, T., Shields, J. J., Byrd, J. B., Rainey, W. E., Auchus, R. J., & Turcu, A. F. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-01299 · Cited by 63
Ng, E., Gwini, S. M., Libianto, R., Choy, K. W., Lu, Z. X., Shen, J., Doery, J. C. G., Fuller, P. J., & Yang, J. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac568 · Cited by 65
Primary aldosteronism and pregnancy
Landau, E., & Amar, L. (2016) · Annales d Endocrinologie · doi:10.1016/j.ando.2016.04.009 · Cited by 64
Subtype Diagnosis of Primary Aldosteronism: Is Adrenal Vein Sampling Always Necessary?
Buffolo, F., Monticone, S., Williams, T. A., Rossato, D., Burrello, J., Tetti, M., Veglio, F., & Mulatero, P. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18040848 · Cited by 70
“Despite being the “gold standard” test to distinguish between unilateral and bilateral PA [6], AVS remains a costly and challenging procedure, and is only routinely available in some tertiary referral centers worldwide [20].”
BackgroundMethodInfluentialAberrant G-protein coupled hormone receptor in adrenal diseases
St‐Jean, M., Ghorayeb, N. E., Bourdeau, I., & Lacroix, A. (2018) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2018.01.003 · Cited by 62
Genetic and Genomic Mechanisms of Primary Aldosteronism
Fernandes-Rosa, F. L., Boulkroun, S., & Zennaro, M. (2020) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2020.05.005 · Cited by 62
Goupil, R., Tsuyuki, R. T., Santesso, N., Terenzi, K. A., Habert, J., Cheng, G., Gysel, S. C., Bruneau, J., Leung, A. A., Campbell, N. R. C., et al. (2025) · Canadian Medical Association Journal · doi:10.1503/cmaj.241770 · Cited by 60
Identification of risk loci for primary aldosteronism in genome-wide association studies
Floch, É. L., Cosentino, T., Larsen, C. K., Beuschlein, F., Reincke, M., Amar, L., Rossi, G. P., Sousa, K. D., Baron, S., Chantalat, S., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32896-8 · Cited by 66
Self-citationTurcu, A. F., Tezuka, Y., Lim, J. S., Salman, Z., Sehgal, K., Liu, H., Larose, S., Parksook, W. W., Williams, T. A., Cohen, D. L., et al. (2024) · Hypertension · doi:10.1161/hypertensionaha.123.21910 · Cited by 60
“16 Substantial heterogeneity in AVS procedural protocols and data interpretation exists even among referral centers, 17 and these differences impact the recommendation for or against surgery.”
BackgroundSelf-citationMulatero, P., Wuerzner, G., Groessl, M., Sconfienza, E., Damianaki, A., Forestiero, V., Vogt, B., Brunner, H. R., Gerlock, T. E., Steele, R., et al. (2024) · EClinicalMedicine · doi:10.1016/j.eclinm.2024.102576 · Cited by 64
“2,5,6 The currently available pharmacological treatments, MRAs, are limited by undesirable side effects at doses required to treat PA and a need for prolonged dose titration at treatment initiation.”
BackgroundInfluentialFunctional imaging with 11C-metomidate PET for subtype diagnosis in primary aldosteronism
Soinio, M., Luukkonen, A.-K., Seppänen, M., Kemppainen, J., Seppänen, J., Pienimäki, J., Leijon, H., Vesterinen, T., Arola, J. T., Lantto, E., et al. (2020) · European Journal of Endocrinology · doi:10.1530/eje-20-0532 · Cited by 64
Metadata
- Authors
- Funder, J. W., Carey, R. M., Mantero, F., Murad, M. H., Reincke, M., Shibata, H., Stowasser, M., & Young, W. F.
- Affiliations
- Hudson Institute of Medical Research (AU)
- University of Virginia Health System (US)
- University of Padua (IT)
- Mayo Clinic (US)
- Klinikum of the Ludwig-Maximilians-University of Munich (M.R.), 80366 München, Bavaria, Germany
- Oita University (JP)
- The University of Queensland (AU)
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2016-05-01
- Volume
- 101
- Issue
- 5
- Pages
- 1889-1916
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2290633895
- Semantic Scholar
- 36716f26ebd3b8e468f352d9132208c41e5688c0
- Cited by
- 2,925
- References
- 241
- Citations by year
- 2026: 236 · 2025: 397 · 2024: 315 · 2023: 329 · 2022: 329 · 2021: 315 · 2020: 293 · 2019: 238 · 2018: 200 · 2017: 188 · 2016: 72
- FWCI
- 233.87
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- INFM-OAR (INFN Catania) (submittedVersion, cc-by-nc-nd)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal Regulation and Hypertension
- Health Sciences › Medicine › Surgery › Adrenal and Paraganglionic Tumors
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Keywords
- primary aldosteronism, case finding, aldosterone-renin ratio, adrenal computed tomography, adrenal vein sampling, laparoscopic adrenalectomy, bilateral adrenal hyperplasia, mineralocorticoid receptor antagonists, hypertension, hypokalemia
- MeSH terms
- Adrenal Glands, Adrenalectomy, Aldosterone, Mineralocorticoid Receptor Antagonists, Humans, Hyperaldosteronism, Renin, Evidence-Based Medicine, Consensus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.